A study led by Case Western Reserve University School of Medicine, in collaboration with the University of East London UK, and Swansea University UK, is the first to show the effects of the drug ...

Often used at dance clubs and concerts, the recreational drug known as ecstasy (MDMA) is dangerous and, in some cases, may even prove deadly (1-2). Even so, a growing body of evidence shows that, in ...

Following the tragic deaths of two MBA students at a late night techno concert at the NESCO Exhibition Centre, investigators are examining the suspected use of Methylenedioxymethamphetamine, commonly ...

A panel of advisers to the U.S. Food and Drug Administration will meet to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder. The meeting is the ...

A new study published in the Journal of Psychopharmacology has found that MDMA’s mood-enhancing effects may be partly driven by changes in brain systems related to serotonin, oxytocin, and vasopressin ...

Efforts to make MDMA legally available as a psychotherapeutic catalyst hit a daunting roadblock on Tuesday when an expert panel overwhelmingly voted to recommend that the Food and Drug Administration ...

Tom Shroder, a former Post editor, is the author of “Acid Test: LSD, Ecstasy, and the Power to Heal.” This month, the Food and Drug Administration denied a new drug application by Lykos Therapeutics ...

A panel of advisers to the U.S. health regulator on Tuesday voted against a therapy based on the party drug MDMA for patients with post-traumatic stress disorder, in a major setback to the nascent ...

For the first time since the 1960s, the Department of Veterans Affairs is studying whether a psychedelic substance is effective for treating mental health conditions -- specifically, post-traumatic ...

Mind Medicine (MindMed) Inc. (MNMD) is a biotech that should be on everyone's watch list. The reason why I state this is that it has been able to make substantial improvements in the MDMA treatment ...

FDA staff raised concerns about the available safety data and limitations in the study design for midomafetamine (MDMA) to treat post-traumatic stress disorder (PTSD) in briefing documents released ...